[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381690-105":59,"doc-detail-381690-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","towards-personalized-treatment-and-molecular-research-on-gastrointestinal-tumors-editorial","Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors - Editorial","","Editorial synthesizing recent progress in the personalized management of gastrointestinal cancers, emphasizing how translational research and precision medicine are reshaping diagnosis and therapy across adjuvant and metastatic settings. It highlights molecular-targeted agents and immunotherapy while noting the persisting gap in predictive efficacy markers. The discussion summarizes emerging evidence on prognostic biomarkers in colorectal cancer, including NGS-derived genetic predisposition and qRT-PCR–based molecular ratios and cancer stem cell marker expression, for improved patient stratification and monitoring.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/towards-personalized-treatment-and-molecular-research-on-gastrointestinal-tumors-editorial/381690/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/towards-personalized-treatment-and-molecular-research-on-gastrointestinal-tumors-editorial/381690.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the editorial’s main theme for gastrointestinal cancers?","Question",{"text":112,"@type":113},"It focuses on personalized treatment supported by molecular research, aiming to improve diagnosis, management, monitoring, and patient stratification for gastrointestinal tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are predictive markers considered insufficient in current gastrointestinal cancer therapy?",{"text":117,"@type":113},"Despite advances from molecular-targeted agents and immunotherapy, predictive markers of efficacy are still lacking, creating challenges for clinicians when choosing treatments and tracking progression.",{"name":119,"@type":110,"acceptedAnswer":120},"Which molecular approaches are discussed for prognostic evaluation in colorectal cancer?",{"text":121,"@type":113},"The text discusses the use of qRT-PCR to measure specific mRNA levels in tissues such as lymph nodes, including combinations and ratios with markers like CEA, as well as evaluation of cancer stem cell–related markers and comparisons of prognostic accuracy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},381690,1790825279,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":24},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Editorial  \nTowards Personalized Treatment and Molecular Research on Gastrointestinal Tumors  \nAlessandro Passardi 1, *, Emanuela Scarpi 2 and Paola Ulivi 3  \nCitation: Passardi, A.; Scarpi, E.; Ulivi, P. Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors. Int. J. Mol. Sci. 2023, 24, 14283. [https://](https://)[ ](https://)[doi.org/10.3390/ijms241814283](doi.org/10.3390/ijms241814283)  \nReceived: 7 April 2023  \nRevised: 5 June 2023  \nAccepted: 30 July 2023  \nPublished: 19 September 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)“Dino Amadori”, Via P. Maroncelli 40, 47014 Meldola, Italy  \n2 Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)“Dino Amadori”, Via P. Maroncelli 40, 47014 Meldola, Italy; [emanuela.scarpi@irst.emr.it](emanuela.scarpi@irst.emr.it)  \n3 Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)“Dino Amadori”, Via P. Maroncelli 40, 47014 Meldola, Italy; [paola.ulivi@irst.emr.it](paola.ulivi@irst.emr.it)  \n* Correspondence: [alessandro.passardi@irst.emr.it](alessandro.passardi@irst.emr.it)  \nGastrointestinal cancers (GC) account for 26% of all cancer incidences and 35% of all cancer-related deaths [1] . Despite the decrease in the incidence of some GC subtypes, this group of tumors still constitutes an important challenge for public health. Recent years have seen remarkable advances in the treatment of GC. In particular, translational research has led to significant benefits in the diagnosis and management of such tumors, and precision medicine is fast becoming the aim of scientific research. Individualized treatment for GC in both adjuvant and metastatic settings is increasingly emphasized. In particular, the introduction of molecular-targeted agents as well as immunotherapy has significantly improved patient outcome; however, predictive markers of efficacy are still lacking. Due to these new therapeutic options, physicians are confronted with new challenges, such as monitoring progression and stratifying patients for appropriate treatments.  \nColorectal cancer (CRC) is the fourth leading cause of cancer mortality worldwide. Both environmental and genetic risk factors are recognized. Among genetic diseases associated with the ereditary form of CRC, Lynch syndrome and Familial Adenomatous Polyposis (FAP) are the best-known. Alongside them, the role of other syndromes is widely recognized, such as, for example Li–Fraumeni, MUTYH-associated polyposis, Peutz–Jeghers, Cowden, and Juvenile Polyposis syndrome. Moreover, Next-Generation Sequencing (NGS) techniques have led to the identification of new genes involved in the predisposition to CRC, as reviewed by F. Rebuzzi and collaborators. The authors concluded by suggesting a choice of wide NGS panels, including the genes involved in the main cancer syndromes and, possibly, the new emerging genes [2] .  \nThe study by Ismail H.T.H and collaborators explored the role of G protein-coupled receptor 55 (GPR55) as a prognostic marker in CRC patients treated with curative surgery. GPR55 acts as a regulator of innate immunity and tumor immunosurveillance, through the activation of T cells and NK cells, as shown in mice models. A new highly specific quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR) assay was used to analyze the mRNA expression levels of GPR55 in 382 regional lymph nodes removed during surgical treatment from 345 patients with CRC. Unexpectedly, the authors found that low levels of GPR55 mRNA in lymph nodes were associated with poor prognos","cbCaia0L5LJsLgNb","https://ap.wps.com/l/cbCaia0L5LJsLgNb","pdf",167098,"English","# Editorial focus\n## Personalized treatment and precision medicine\n## Molecular prognostic markers in colorectal cancer\n## Cancer stem cell markers and qRT-PCR performance\n## Translational needs for pancreatic neuroendocrine tumors","[{\"question\":\"What is the editorial’s main theme for gastrointestinal cancers?\",\"answer\":\"It focuses on personalized treatment supported by molecular research, aiming to improve diagnosis, management, monitoring, and patient stratification for gastrointestinal tumors.\"},{\"question\":\"Why are predictive markers considered insufficient in current gastrointestinal cancer therapy?\",\"answer\":\"Despite advances from molecular-targeted agents and immunotherapy, predictive markers of efficacy are still lacking, creating challenges for clinicians when choosing treatments and tracking progression.\"},{\"question\":\"Which molecular approaches are discussed for prognostic evaluation in colorectal cancer?\",\"answer\":\"The text discusses the use of qRT-PCR to measure specific mRNA levels in tissues such as lymph nodes, including combinations and ratios with markers like CEA, as well as evaluation of cancer stem cell–related markers and comparisons of prognostic accuracy.\"}]","Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors - Editorial | PDF",1790246503]